Prescribing information



ATECTURA BREEZHALER is indicated as a maintenance treatment for asthma in adults and adolescents 12 years of age and older, not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.1



  1. ATECTURA BREEZHALER Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | February 2021 | 103413

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at